Ken Griffin Scholar Rock Holding Corp Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.63 - $9.71 $182,357 - $232,069	23,900 Added 314.47%	31,500 $252,000
Q2 2024 Aug 14, 2024	BUY	$7.84 - $16.79 $16,464 - $35,259	2,100 Added 38.18%	7,600 $63,000
Q1 2024 May 15, 2024	SELL	$13.2 - $17.76 $212,520 - $285,936	-16,100 Reduced 74.54%	5,500 $97,000
Q4 2023 Feb 14, 2024	BUY	$6.52 - $20.32 $94,540 - $294,640	14,500 Added 204.23%	21,600 $406,000
Q3 2023 Nov 14, 2023	BUY	$6.02 - $7.76 $42,742 - $55,096	7,100 New	7,100 $50,000
Q1 2023 May 15, 2023	BUY	$7.36 - $12.72 $36,800 - $63,600	5,000 Added 1666.67%	5,300 $42,000
Q4 2022 Feb 14, 2023	BUY	$7.02 - $9.76 $2,106 - $2,928	300 New	300 $2,000

175

75.6M

585K

862K

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $2.35B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.